A phase 1, randomized, double-blind, placebo-controlled, dose-escalating study to evaluate safety, tolerability, and immunogenicity of leish-111f + MPL-SE vaccine in combination with pentavalent antimony in treatment of mucosal leishmaniasis.
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2009
At a glance
- Drugs LEISH-F3 peptide vaccine (Primary) ; Monophosphoryl lipid A (Primary) ; Antiprotozoals
- Indications Leishmaniasis
- Focus Adverse reactions
- 17 Oct 2005 New trial record.